The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Arcus Biosciences (RCUS) announced that Gilead’s (GILD) time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr.

Shares of Arcus Biosciences (NYSE:RCUS) hit a new 52-week low on Tuesday after the biotech said that Gilead Sciences’ (NASDAQ:GILD) option rights to partner with the company for a potential anticancer ...

A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily (BID) casdatifan monotherapy cohort of the Phase 1/1b ARC-20 study; mPFS was not yet reached for other ...

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute ...